Trusted Resource for Clinical Trials, Protocols & Progress
Data management is central to the integrity of clinical trial results. Sponsors are ultimately responsible for ensuring that Case Report Forms (CRFs), Electronic Data Capture (EDC) systems, and safety databases reflect accurate and consistent data. Oversight failures in data management frequently appear in regulatory audit findings issued by the FDA, EMA, and MHRA.
Click to read the full article.
Good Clinical Practice (GCP) training is the foundation of regulatory compliance in clinical research. It ensures that investigators, site staff, and sponsor teams conduct trials in line with ICH GCP, FDA 21 CFR Part 312, and EMA GCP guidelines. Regulatory inspectors routinely review training records during audits to verify that personnel are qualified and continuously updated in compliance practices.
Click to read the full article.
Clinical investigators play a central role in safeguarding participant safety and ensuring trial credibility. Regulators including the FDA, EMA, and MHRA emphasize that investigators must demonstrate adequate knowledge of the protocol, ICH GCP guidelines, and applicable local regulations. When investigators lack sufficient knowledge or training, it frequently results in audit findings, raising concerns about oversight, protocol adherence, and ethical conduct.
Click to read the full article.
Standard Operating Procedures (SOPs) provide the framework for conducting clinical trials in compliance with ICH GCP, FDA 21 CFR Part 312, and EMA guidelines. They define responsibilities, ensure consistency, and safeguard both data integrity and patient safety. Non-compliance with SOPs is one of the most frequently reported regulatory audit findings, as it highlights systemic weaknesses in training, oversight, and documentation.
Click to read the full article.
Contract Research Organizations (CROs) play a critical role in clinical trials, handling key responsibilities such as monitoring, data management, and safety reporting. Regulatory agencies including the FDA, EMA, and MHRA expect CRO staff to be fully trained in ICH GCP, protocol-specific requirements, and sponsor Standard Operating Procedures (SOPs). Training deficiencies at CROs are a recurring regulatory audit finding, often raising concerns about the adequacy of sponsor oversight.
Click to read the full article.
Ethics Committees (ECs), also referred to as Institutional Review Boards (IRBs), safeguard the rights, safety, and well-being of clinical trial participants. Regulatory agencies including the FDA, EMA, and MHRA require that EC/IRB members be trained in ICH GCP, applicable local laws, and ethical principles such as the Declaration of Helsinki. Training deficiencies among ethics committee members are a recurring regulatory audit finding, raising concerns about oversight effectiveness and participant protection.
Click to read the full article.
Training in Good Clinical Practice (GCP) and trial-specific procedures is not a one-time requirement. Regulators including the FDA, EMA, and MHRA emphasize the importance of periodic refresher training to ensure continuous compliance with evolving protocols, SOPs, and regulatory expectations.
Click to read the full article.
Investigator sites are the operational core of clinical trials, responsible for patient recruitment, data collection, and adherence to trial protocols. Regulatory authorities such as the FDA, EMA, and MHRA regularly audit investigator sites to ensure compliance with ICH GCP standards. Findings of GCP non-compliance at sites are among the most frequent audit observations and may jeopardize trial validity, regulatory submissions, and participant safety.
Click to read the full article.
Investigator meetings are designed to ensure that all site investigators and study staff receive consistent training on the clinical trial protocol, Good Clinical Practice (GCP) requirements, and sponsor Standard Operating Procedures (SOPs). Regulatory agencies such as the FDA, EMA, and MHRA require sponsors to maintain complete documentation of these meetings. Poor or missing documentation is a recurring regulatory audit finding, raising questions about oversight and the adequacy of trial preparation.
Click to read the full article.
Clinical trial protocols define the scientific, ethical, and operational framework of a study. They specify eligibility criteria, dosing regimens, visit schedules, safety assessments, and data collection methods. Regulators such as the FDA, EMA, and MHRA expect investigators, sponsors, and CROs to follow protocol requirements precisely. However, misinterpretation of protocols remains a frequent cause of regulatory audit findings, often leading to protocol deviations, compromised data integrity, and patient safety concerns.
Click to read the full article.
